<Back to Therapeutic Areas


Pathophysiology of COVID-19 (2:25)

An Evolving Target: Variants of SARS-Cov-2 (4:30)

Severe COVID-19 and GM-CSF (2:19)

GSK COVID Therapeutics will have a presence at the meetings listed below. Please visit us at our scientific booths to view our scientific information.

Meet Us

SHM | May 3-7, 2021 | Virtual

ATS | May 14-19, 2021 | Virtual

AAEM21 | Jun 20-24, 2021 | St. Louis, MO | Virtual

NMA | Jul 17-20, 2021 | Virtual

AAFP | Sep 28-Oct 2, 2021 | Virtual

IDWeek | Sep 29-Oct 3, 2021 | San Diego, CA

Critical Concepts in Emergency Medicine | Sep 30-Oct 2, 2021 | New Orleans, LA

CHEST | Oct 24-27, 2021 | Vancouver, Canada

ACEP | Oct 25-28, 2021 | Boston, MA

ACAAI | Nov 4-8, 2021 | New Orleans, LA

ACR | Nov 5-9, 2021 | San Francisco, CA

AARC | Nov 6-9, 2021 | Phoenix, AZ

Sotrovimab has not been approved but has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Sotrovimab is not authorized for use in patients who are hospitalized due to COVID-19, who require oxygen therapy due to COVID-19, or who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity). Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID-19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

The emergency use of sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

If you have a question, please contact the GSK COVID Contact Center.

9 AM - 6 PM ET, Monday - Friday, with after hours pager service available

View our ongoing, innovative research to the COVID-19 Pandemic.

Phase II Phase III Phase IV

OSCAR: Investigating Otilimab in Patients with Severe Pulmonary COVID-19 Related Disease


COMET-ICE: VIR-7831 for the Early Treatment of COVID-19 in Outpatients


COMET-PEAK: Safety, Tolerability, and Pharmacokinetics of Second Generation VIR-7831 in Non-hospitalized Patients with mild to Moderate COVID-19


COMET-TAIL: Intramuscular Sotrovimab (VIR-7831) for Mild/Moderate COVID-19.


BLAZE-4: A Study of Immune System Proteins in Participants with Mild to Moderate COVID-19 Illness sponsored by Eli Lilly and Company

  • *VIR-7831 is being developed in a collaboration between GSK and Vir Biotechnology

Antibody Collaborations (0.27)

COVID-19 Immunology (0.29)

What are Variants (0.44)

What is Antibody Therapy (0.42)

  Contact Us